DAKAR: The families of 20 Gambian children who lost their lives after consuming cough syrups made in India are preparing to take legal action against their government this month, alleging mishandling of drug imports. The case sheds light on the devastating impact of the contaminated medicines and the challenges faced by victims seeking justice in one of Africa’s poorest nations.
The parents’ allegations, as detailed in court documents shared exclusively with Reuters, reveal the panic, confusion, and heartbreak experienced within an already strained healthcare system. The World Health Organization (WHO) has linked at least 70 deaths in Gambia last year to medicines manufactured by Indian drugmaker Maiden Pharmaceuticals, which were found to be contaminated with diethylene glycol (DEG) and ethylene glycol (EG), industrial solvents and antifreeze agents.
The lawsuit, seeking approximately $250,000 in compensation for each child, targets Gambia’s health ministry, the drug regulator, and Maiden Pharmaceuticals. This high-profile case, supported by pro bono lawyers, challenges the authorities’ failure to uphold their own laws regarding the importation and safety of drugs in the country.
Gambia’s Health Spending and Facilities
Gambia’s limited health spending and lack of testing facilities raise concerns about the risks associated with importing drugs without proper verification. The case highlights the global issue of tainted medicines affecting vulnerable populations, often without a clear path to justice for the victims.
The first hearing is scheduled for July 17, with the defendants given 30 days to respond. Gambia’s health ministry, which has initiated an investigation into the incident, did not comment on the matter. The World Bank has approved funding for the construction of a medicines testing lab in Gambia, aiming to prevent similar tragedies in the future.
The testimonies provided by the parents reveal a healthcare system ill-equipped to respond once the contaminated syrups reached pharmacies. Delays in receiving urgent medical attention and misdiagnoses were reported, exacerbating the children’s conditions. The parents’ statements also detail instances of lacking essential medical supplies and inadequate hospital care.
This case, unlike previous incidents, has gained significant attention due to the scale of the tragedy and the involvement of pro bono lawyers. The families are determined to seek accountability and challenge the lack of oversight and regulation in the pharmaceutical trade. With no penalties imposed thus far in Gambia or India, the lawsuit highlights the urgent need for stronger regulatory measures and enhanced drug safety standards.
